Home » Congressmen Ask FDA To Explain CBER Hacking

Congressmen Ask FDA To Explain CBER Hacking

December 13, 2013

Pharmaceuticals Regulatory Affairs Submissions and Approvals Commercial Operations

Lawmakers want the FDA to explain how hackers broke in to the CBER online submission system to steal personal user information and what the FDA has done to prevent a recurrence.

To View This Article:

Login

Buy This Article Now

Add this article to your cart for $25.00

26Jan
Reducing Complexity in Starting Clinical Trials – More Patients, Faster Startup
27Jan
Medical Device Clinical Trials in China: Latest Regulatory Developments
27Jan
FDA’s Response to COVID-19: Fundamentals of Obtaining Emergency Use Authorizations
09Feb
Maintaining Your Risk-Based Cleaning and Disinfectant Programs: Best Practices During COVID-19
10Feb
FDA Under the Biden Administration: What’s to Come and What It Will Mean
11Feb
Lab X.0: Addressing Quality and Compliance Challenges in Laboratory Operations in the COVID-19 All-Digital Era

Congressmen Ask FDA To Explain CBER Hacking

To View This Article:

Login

Buy This Article Now

Upcoming Events

Reducing Complexity in Starting Clinical Trials – More Patients, Faster Startup

Medical Device Clinical Trials in China: Latest Regulatory Developments

FDA’s Response to COVID-19: Fundamentals of Obtaining Emergency Use Authorizations

Maintaining Your Risk-Based Cleaning and Disinfectant Programs: Best Practices During COVID-19

FDA Under the Biden Administration: What’s to Come and What It Will Mean

Lab X.0: Addressing Quality and Compliance Challenges in Laboratory Operations in the COVID-19 All-Digital Era

Featured Products

Biological Risk Evaluation and Management for Medical Devices

GMP Inspection Preparation Checklist: A Tool for Internal Auditing

Featured Stories

Supreme Court Rejects Merck’s Appeal for $2.5 Billion Patent Verdict Reinstatement

FDA Clears SCC’s Transfusion-Management Software

MiRXES Earns CE Mark for COVID-19/Flu Test

Kite Pharma’s Tecartus Gains UK Recommendation for Lymphoma

The Revised ICH E8: A Guide to New Clinical Trial Requirements